dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: 0B. DAX-like receptors (type: nhr)
Target: SHP

Ligand: compound 10 [PMID: 18759424] (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 6.300000190734863 pIC50
Reference (Journal): Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and inhibition of SRC homology 2 domain-containing protein tyrosine phosphatase-2 activity.
Published in: J Med Chem
Target family: 1.1.1.42 Isocitrate dehydrogenases (type: enzyme)
Target: isocitrate dehydrogenase (NADP(+)) 2

Ligand: enasidenib (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: yes
Approval source: FDA (2017)
Primary target: no
Median affinity:  -
Reference (Patent): Therapeutically active compounds and their methods of use.

Ligand: LY3410738 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.050000190734863 pIC50
Reference (Patent): 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors

Ligand: vorasidenib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma.
Published in: ACS Med Chem Lett
Target family: 1.1.1.42 Isocitrate dehydrogenases (type: enzyme)
Target: isocitrate dehydrogenase (NADP(+)) 1

Ligand: ivosidenib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2018), EMA (2023)
Primary target: yes
Median affinity:  -
Reference (Patent): Therapeutically active compounds and their methods of use

Ligand: LY3410738 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.199999809265137 pIC50
Reference (Patent): 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors

Ligand: AGI-5198 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 4.889999866485596 pKi

Ligand: LY3410738 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.980000019073486 pIC50
Reference (Patent): 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors

Ligand: olutasidenib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2022)
Primary target: no
Median affinity:  pIC50
Reference (Patent): Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors

Ligand: safusidenib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.889999866485596 pIC50
Reference (Journal): A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model.
Published in: Mol Cancer Ther

Ligand: vorasidenib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma.
Published in: ACS Med Chem Lett
Target family: 1.13.11.- Dioxygenases (type: enzyme)
Target: indoleamine 2,3-dioxygenase 1

Ligand: navoximod (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.239999771118164 pKi
Reference (Journal): Discovery of Clinical Candidate (1<i>R</i>,4<i>r</i>)-4-((<i>R</i>)-2-((<i>S</i>)-6-Fluoro-5<i>H</i>-imidazo[5,1-<i>a</i>]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (Navoximod), a Potent and Selective Inhibitor of Indoleamine 2,3-Dioxygenase 1.
Published in: J Med Chem

Ligand: necrostatin-1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.940000057220459 pKi
Reference (Journal): Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.
Published in: Nat Med
Target family: 1.13.11.- Dioxygenases (type: enzyme)
Target: indoleamine 2,3-dioxygenase 2

Ligand: tryptanthrin 5i (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.739999771118164 pIC50
Reference (Journal): Establishment of a human indoleamine 2, 3-dioxygenase 2 (hIDO2) bioassay system and discovery of tryptanthrin derivatives as potent hIDO2 inhibitors.
Published in: Eur J Med Chem

Ligand: tryptanthrin 5i (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.010000228881836 pKi
Reference (Journal): Establishment of a human indoleamine 2, 3-dioxygenase 2 (hIDO2) bioassay system and discovery of tryptanthrin derivatives as potent hIDO2 inhibitors.
Published in: Eur J Med Chem

Ligand: example 184 [WO2014186035] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6 pIC50
Reference (Patent): Inhibitors of the kynurenine pathway
Target family: 1.13.11.- Dioxygenases (type: enzyme)
Target: indoleamine 2,3-dioxygenase 1

Ligand: tryptanthrin 5i (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.989999771118164 pIC50
Reference (Journal): Establishment of a human indoleamine 2, 3-dioxygenase 2 (hIDO2) bioassay system and discovery of tryptanthrin derivatives as potent hIDO2 inhibitors.
Published in: Eur J Med Chem

Ligand: tryptanthrin 5i (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.269999980926514 pKi
Reference (Journal): Establishment of a human indoleamine 2, 3-dioxygenase 2 (hIDO2) bioassay system and discovery of tryptanthrin derivatives as potent hIDO2 inhibitors.
Published in: Eur J Med Chem

Ligand: tryptanthrin (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.320000171661377 pKi
Reference (Journal): Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice.
Published in: J Med Chem

Ligand: PF-06840003 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.820000171661377 pIC50
Reference (Patent): Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors.
Target family: 1.13.11.- Dioxygenases (type: enzyme)
Target: tryptophan 2,3-dioxygenase

Ligand: navoximod (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6 pIC50
Reference (Journal): Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway.
Published in: J Med Chem

Ligand: LM10 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 5.25 pKi
Reference (Journal): Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase.
Published in: Proc Natl Acad Sci USA

Ligand: LM10 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.210000038146973 pIC50
Reference (Journal): Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase.
Published in: Proc Natl Acad Sci USA

Ligand: LM10 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.710000038146973 pIC50
Reference (Journal): Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase.
Published in: Proc Natl Acad Sci USA

Ligand: LM10 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 5.25 pKi
Reference (Journal): Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.
Published in: J Med Chem
Target family: 1.13.11.- Dioxygenases (type: enzyme)
Target: indoleamine 2,3-dioxygenase 2

Ligand: tryptanthrin 5i (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.349999904632568 pIC50
Reference (Journal): Establishment of a human indoleamine 2, 3-dioxygenase 2 (hIDO2) bioassay system and discovery of tryptanthrin derivatives as potent hIDO2 inhibitors.
Published in: Eur J Med Chem
Target family: 1.13.11.- Dioxygenases (type: enzyme)
Target: indoleamine 2,3-dioxygenase 1

Ligand: 1-methyl-L-tryptophan (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.369999885559082 pKi
Reference (Journal): Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice.
Published in: J Med Chem

Ligand: amg-1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.519999980926514 pIC50
Reference (Journal): Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors.
Published in: Biochim Biophys Acta

Ligand: beta-carboline (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 0.9200000166893005 pKi
Reference (Journal): Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors.
Published in: Bioorg Med Chem

Ligand: compound 8u [PMID: 31999451] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.099999904632568 pKd
Reference (Journal): Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3.
Published in: J Med Chem

Ligand: epacadostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.170000076293945 pIC50
Reference (Journal): Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model.
Published in: J Med Chem

Ligand: linrodostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form.
Published in: Proc Natl Acad Sci USA

Ligand: LW106 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.800000190734863 pIC50
Reference (Journal): LW106, a novel indoleamine 2,3-dioxygenase 1 inhibitor, suppresses tumour progression by limiting stroma-immune crosstalk and cancer stem cell enrichment in tumour micro-environment.
Published in: Br J Pharmacol
Target family: 1.14.11.- Histone demethylases (type: enzyme)
Target: lysine demethylase 3A

Ligand: IOX1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7 pIC50
Reference (Journal): A cell-permeable ester derivative of the JmjC histone demethylase inhibitor IOX1.
Published in: ChemMedChem
Target family: 1.14.11.- Histone demethylases (type: enzyme)
Target: lysine demethylase 2A

Ligand: IOX2 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.28000020980835 pIC50
Reference (Journal): Selective small molecule probes for the hypoxia inducible factor (HIF) prolyl hydroxylases.
Published in: ACS Chem Biol

Ligand: daminozide (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.820000171661377 pIC50
Reference (Journal): Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
Published in: J Med Chem
Target family: 1.14.11.- Histone demethylases (type: enzyme)
Target: lysine demethylase 1A

Ligand: tranylcypromine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1961)
Primary target: no
Median affinity: 4.400000095367432 pIC50
Reference (Journal): A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency.
Published in: MBio

Ligand: TAK-418 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.539999961853027 pIC50
Reference (Journal): LSD1 enzyme inhibitor TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models.
Published in: Sci Adv

Ligand: RN-1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity:  pIC50
Reference (Journal): Brain-penetrant LSD1 inhibitors can block memory consolidation.
Published in: ACS Chem Neurosci

Ligand: ORY-1001 (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: yes
Median affinity: 7.699999809265137 pIC50
Reference (Journal): KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease.
Published in: Epigenomics

Ligand: NCL-1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.800000190734863 pIC50
Reference (Journal): Synthesis and biological activity of optically active NCL-1, a lysine-specific demethylase 1 selective inhibitor.
Published in: Bioorg Med Chem

Ligand: GSK-LSD1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.800000190734863 pIC50
Reference (Webpage): GSK-LSD1 - a chemical probe for LSD1.

Ligand: GSK2879552 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.400000095367432 pIC50
Reference (Patent): Cyclopropylamines as lsd1 inhibitors

Ligand: CC-90011 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.520000457763672 pIC50
Reference (Journal): Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1)
Published in: J Med Chem

Ligand: OG-L002 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.699999809265137 pIC50
Reference (Journal): A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency.
Published in: MBio
Target family: 1.14.11.- Histone demethylases (type: enzyme)
Target: PHD finger protein 8

Ligand: daminozide (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.260000228881836 pIC50
Reference (Journal): Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
Published in: J Med Chem
Target family: 1.14.11.- Histone demethylases (type: enzyme)
Target: lysine demethylase 7A

Ligand: daminozide (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.679999828338623 pIC50
Reference (Journal): Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
Published in: J Med Chem
Target family: 1.14.11.- Histone demethylases (type: enzyme)
Target: lysine demethylase 6B

Ligand: zavondemstat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Patent): Histone demethylase inhibitors

Ligand: IOX1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.800000190734863 pIC50
Reference (Journal): A cell-permeable ester derivative of the JmjC histone demethylase inhibitor IOX1.
Published in: ChemMedChem

Ligand: GSK-J4 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.070000171661377 pIC50
Reference (Journal): Inhibition of demethylases by GSK-J1/J4.
Published in: Nature

Ligand: GSK-J1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response.
Published in: Nature

Ligand: GSK-J1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Inhibition of demethylases by GSK-J1/J4.
Published in: Nature

Ligand: compound 3 [PMID: 29633584] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 5.820000171661377 pIC50
Reference (Journal): Virtual Fragment Screening Identification of a Quinoline-5,8-dicarboxylic Acid Derivative as a Selective JMJD3 Inhibitor.
Published in: ChemMedChem
Target family: 1.14.11.- Histone demethylases (type: enzyme)
Target: lysine demethylase 6A

Ligand: KDM5 inhibitor N71 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.21999979019165 pIC50
Reference (Journal): Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A.
Published in: J Med Chem

Ligand: GSK-J4 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.179999828338623 pIC50
Reference (Journal): Inhibition of demethylases by GSK-J1/J4.
Published in: Nature

Ligand: GSK-J1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.28000020980835 pIC50
Reference (Journal): Inhibition of demethylases by GSK-J1/J4.
Published in: Nature
Target family: 1.14.11.- Histone demethylases (type: enzyme)
Target: lysine demethylase 5C

Ligand: PBIT (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.309999942779541 pIC50
Reference (Journal): Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen.
Published in: J Biol Chem

Ligand: IOX2 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.800000190734863 pIC50
Reference (Journal): Selective small molecule probes for the hypoxia inducible factor (HIF) prolyl hydroxylases.
Published in: ACS Chem Biol

Ligand: GSK-J4 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.820000171661377 pIC50
Reference (Journal): Inhibition of demethylases by GSK-J1/J4.
Published in: Nature

Ligand: GSK-J1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.260000228881836 pIC50
Reference (Journal): Inhibition of demethylases by GSK-J1/J4.
Published in: Nature
Target family: 1.14.11.- Histone demethylases (type: enzyme)
Target: lysine demethylase 5B

Ligand: PBIT (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.519999980926514 pIC50
Reference (Journal): Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen.
Published in: J Biol Chem

Ligand: KDOAM25 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.71999979019165 pIC50
Reference (Journal): Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells.
Published in: Cell Chem Biol

Ligand: KDM5 inhibitor N71 (Synthetic organic)
Interaction type: Inhibitor
Action: Irreversible inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.659999847412109 pIC50
Reference (Journal): Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A.
Published in: J Med Chem

Ligand: GSK-J4 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.010000228881836 pIC50
Reference (Journal): Inhibition of demethylases by GSK-J1/J4.
Published in: Nature

Ligand: GSK-J1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.769999980926514 pIC50
Reference (Journal): Inhibition of demethylases by GSK-J1/J4.
Published in: Nature

Ligand: Compound 9 [doi:10.26434/chemrxiv.7072592.v1] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.519999980926514 pIC50
Reference (Journal): Design, Synthesis and Characterization of Covalent KDM5 Inhibitors.
Published in: Angew Chem Int Ed Engl
Target family: 1.14.11.- Histone demethylases (type: enzyme)
Target: lysine demethylase 5A

Ligand: PBIT (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.21999979019165 pIC50
Reference (Journal): Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen.
Published in: J Biol Chem

Ligand: KDM5 inhibitor N71 (Synthetic organic)
Interaction type: Inhibitor
Action: Irreversible inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.489999771118164 pIC50
Reference (Journal): Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A.
Published in: J Med Chem

Ligand: GSK-J1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.170000076293945 pIC50
Reference (Journal): Inhibition of demethylases by GSK-J1/J4.
Published in: Nature
Target family: 1.14.11.- Histone demethylases (type: enzyme)
Target: lysine demethylase 4E

Ligand: ML324 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.039999961853027 pIC50
Reference (Journal): Discovery of ML324, a JMJD2 demethylase inhibitor with demonstrated antiviral activity
Published in: Probe Reports from the NIH Molecular Libraries Program

Ligand: compound 6a [PMID: 18942826] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.849999904632568 pIC50
Reference (Journal): Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases.
Published in: J Med Chem